The Use of Palliative Radiotherapy in the Treatment of Lung Cancer |
| |
| Affiliation: | 1. The Christie Hospital NHS Foundation Trust, Manchester, UK;2. Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Broomhall, Sheffield, UK;1. Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, UK;2. University Hospitals Sussex NHS Foundation Trust, West Sussex, UK;1. Department of Nuclear Medicine, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey;2. Department of Nuclear Medicine, Gazi University Faculty of Medicine, Ankara, Turkey;3. Department of General Surgery, Gazi University Faculty of Medicine, Ankara, Turkey;4. Department of Internal Medicine, Division of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey;5. Department of Pathology, Gazi University Faculty of Medicine, Ankara, Turkey;1. Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan;2. Department of Radiology, Kansai Medical University Medical Center, Osaka, Japan;1. Department of Radiation Oncology, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Kharghar, Navi Mumbai, India;2. Clinical Research Secretariat, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Kharghar, Navi Mumbai, India;1. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;2. Department of Cardiothoracic Surgery, The Royal Melbourne Hospital, Melbourne, Victoria, Australia;3. School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia;4. Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia;5. Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia |
| |
| Abstract: | There have been significant advances in the systemic treatment of stage IV lung cancer, which is now recommended first line in patients with adequate fitness. This includes some patients with brain metastases due to the increased understanding of the central nervous system penetration of targeted therapies. The trials evidence base for palliative radiotherapy pre-dated this routine use of systemic therapy in our practice, which means that the sequence and role of palliative radiotherapy are not currently well defined in the first-line treatment setting. However, due to its efficacy in symptom control, radiotherapy remains a core component in the palliative management of lung cancer, particularly in the second-line setting and those unsuited to primary systemic treatment. This overview focuses on the evidence behind palliative radiotherapy to the thorax and brain for non-small cell and small cell lung cancer and the potential for future studies, including the TOURIST Trial Platform, to guide the future direction of these treatments. |
| |
| Keywords: | Brain metastases lung cancer radiotherapy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
